New drugs, therapeutic strategies, and future direction for the treatment of pulmonary arterial hypertension

Valentina Mercurio, Anna Bianco, Giacomo Campi, Alessandra Cuomo, Nermin Diab, Angela Mancini, Paolo Parrella, Mario Petretta, Paul M. Hassoun, Domenico Bonaduce

Research output: Contribution to journalReview article

Abstract

Despite recent advances in Pulmonary Arterial Hypertension (PAH) treatment, this condition is still characterized by an extremely poor prognosis. In this review, we discuss the use of newly-approved drugs for PAH treatment with already known mechanisms of action (macitentan), innovative targets (riociguat and selexipag), and novel therapeutic approaches with initial up-front combination therapy. Secondly, we describe new potential signaling pathways and investigational drugs with promising role in the treatment of PAH.

Original languageEnglish (US)
Pages (from-to)2844-2864
Number of pages21
JournalCurrent medicinal chemistry
Volume26
Issue number16
DOIs
StatePublished - Jan 1 2019

Keywords

  • Gene therapy
  • Immunity
  • Inflammation
  • Initial combination therapy
  • Macitentan
  • Metabolism
  • Pulmonary arterial denervation
  • Pulmonary arterial hypertension
  • Riociguat
  • Selexipag
  • Serotonin

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Fingerprint Dive into the research topics of 'New drugs, therapeutic strategies, and future direction for the treatment of pulmonary arterial hypertension'. Together they form a unique fingerprint.

  • Cite this

    Mercurio, V., Bianco, A., Campi, G., Cuomo, A., Diab, N., Mancini, A., Parrella, P., Petretta, M., Hassoun, P. M., & Bonaduce, D. (2019). New drugs, therapeutic strategies, and future direction for the treatment of pulmonary arterial hypertension. Current medicinal chemistry, 26(16), 2844-2864. https://doi.org/10.2174/0929867325666180201095743